A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
for Psoriasis
40 locations incl. Phoenix
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT06857942·Phase 4·Recruiting·Listed Mar 2025